Related Experiment Video
Updated: Jul 13, 2025
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Towards multi-target glioblastoma therapy: Structural, distribution, and functional insights into protein target
Emily Anas1, Emma Hoover1, Anetta L Ille2
1STEM Biomedical, Kitchener, Ontario, Canada.
Abstract:
Glioblastoma is the most commonly occurring and most lethal primary brain tumor. Treatment options are limited in number and therapeutic development remains a major challenge. However, substantial progress has been made in better understanding the underlying biology of the disease. A recent proteomic meta-analysis revealed that 270 proteins were commonly dysregulated in glioblastoma, highlighting the complexity of the disease. This motivated us to explore potential protein targets which may be collectively inhibited, based on common upregulation, as part of a multi-target therapeutic strategy. Herein, we identify and characterize structural attributes relevant to the druggability of six protein target candidates. Computational analysis of crystal structures revealed druggable cavities in each of these proteins, and various parameters of these cavities were determined. For proteins with inhibitor-bound structures available, inhibitor compounds were found to overlap with the computationally determined cavities upon structural alignment. We also performed bioinformatic analysis for normal transcriptional expression distribution of these proteins across various brain regions and various tissues, as well as gene ontology curation to gain functional insights, as this information is useful for understanding the potential for off-target adverse effects. Our findings represent initial steps towards the development of multi-target glioblastoma therapy and may aid future work exploring similar therapeutic strategies.
Insights
Researchers identified druggable protein targets for glioblastoma, a lethal brain cancer. This study explores multi-target therapies by analyzing protein structures and expression, aiming to improve treatment options.
Area of Science:
- Oncology
- Biochemistry
- Computational Biology
Background:
- Glioblastoma is the most lethal primary brain tumor with limited treatment options.
- Proteomic analysis reveals 270 commonly dysregulated proteins in glioblastoma, indicating disease complexity.
- Developing multi-target therapeutic strategies is crucial for advancing glioblastoma treatment.
Approach:
- Identified six potential protein targets for glioblastoma based on common upregulation.
- Characterized structural attributes and druggable cavities of candidate proteins using computational analysis.
- Performed bioinformatic analysis of protein expression and gene ontology for potential off-target effects.
Key Points:
- Druggable cavities were computationally identified in all six candidate proteins.
- Existing inhibitor compounds overlapped with predicted cavities in structural alignments.
- Bioinformatic analysis provided insights into normal expression patterns and potential adverse effects.
Conclusions:
- The study presents initial steps toward developing multi-target glioblastoma therapies.
- Findings may guide future research into similar therapeutic strategies for brain tumors.
- Characterizing druggable targets is essential for novel glioblastoma treatment development.
